1. Scrip
  2. >>Therapy Areas

Vicore ASPIREs To Be Major IPF Player As Sanofi Jumps Onboard

 
• By Kevin Grogan

The Swedish company is well positioned, and well financed with a bit of help from the French major, to push its idiopathic pulmonary fibrosis hopeful buloxibutid closer to the regulatory finishing line.

Ahmed Mousa
Ahmed Mousa • Source: Vicore

Sweden's Vicore Pharma  can now boast Sanofi as a backer as it kicks off mid-stage trials of its idiopathic pulmonary fibrosis (IPF) candidate, buloxibutid.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Respiratory

More from Therapy Areas